Data Sheet (Cat.No.T14570)

BI 99179

Chemical Properties



CAS No. : 1291779-76-4

Formula: C23H25N3O3

Molecular Weight: 391.46

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BI 99179 is a selective and potent inhibitor of type I fatty acid synthase (FAS), a tool compound for targeting FAS for cancer research.
Targets(IC50)	Fatty Acid Synthase
In vitro	BI 99179 demonstrated significant efficacy in mouse hypothalamic N-42 cells with an IC50 of 0.6 μM and no significant LDH release below 30 μM in cytotoxicity assays. [1] BI 99179 showed antiproliferative effects in human glioma GAMG cells at concentrations of 1, 2 and 4 μM. [2]
In vivo	Pharmacokinetically, BI 99179 also performed very well in male Han/Wistar rats, with a half-life (t1/2) of 3.0 hours at an oral dose of 4 mg/kg. [1]

Solubility Information

Solubility	DMSO: 100 mg/mL (255.45 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.22 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5545 mL	12.7727 mL	25.5454 mL
5 mM	0.5109 mL	2.5545 mL	5.1091 mL
10 mM	0.2555 mL	1.2773 mL	2.5545 mL
50 mM	0.0511 mL	0.2555 mL	0.5109 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kley JT, et al. Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.Bioorg Med Chem Lett. 2011 Oct 1;21(19):5924-7.

Singha PK, et al. Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells. Eur J Pharm Sci. 2020 Apr 7;149:105321.